ticilimumab

PreclinicalMonoclonal antibody

VVanderbilt-Ingram Cancer Center

ticilimumab is one of 46 biologic programs targeting Metastatic Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Metastatic MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Metastatic Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

31 2

Yervoy

Bristol-Myers Squibb

Phase 3

43 3

Keytruda

Merck & Co.

Phase 3

39 4

Fludara

Sanofi

Phase 3

21 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

44 6

Rifadin

Imbruvica

2 8

Mektovi

Pfizer

Phase 3

6 9

Braftovi

Pfizer

Phase 3

5 10

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Terminated·VVanderbilt-Ingram Cancer Center··NCT00897312·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ticilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ticilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ticilimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt-Ingram Cancer Center

ticilimumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News